Association between plasma glucosylsphingosine levels and dyskinesia burden in GBA1-related Parkinson's disease
Neurobiology of Disease · 2026-02 · 219 · 107271
DOI: 10.1016/j.nbd.2026.107271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurobiology of Disease, 2026-02. Verfasst von Massimo Marano und 50 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Neurology, Neurophysiology, Neurobiology and Psychiatry, Department of Medicine, University Campus Bio-Medico of Rome, Rome, Italy; Fondazion…. Hauptthemen laut MEDLINE: Glucosylceramidase, Parkinson Disease, Psychosine, Dyskinesias. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
BACKGROUND: GBA1 mutation is the most significant genetic risk factor for Parkinson's disease (PD). It encodes glucocerebrosidase (GCase), whose dysfunction - seen in Gaucher disease - leads to the accumulation of glucosylceramide and its derivate glucosylsphingosine (GlcSph). However, it remains unclear whether GCase and GlcSph are relevant in PD patients carrying no or monoallelic GBA1 variants, and what their clinical impact might be. OBJECTIVE: Investigating the relationships between GBA1 mutations, GCase, GlcSph, and clinical features in a large PD cohort. METHODS: We performed a cross-sectional study of PD patients screened for GBA1 mutations, GCase activity, and GlcSph via dried blood spot tests. Patients were classified as heterozygous mutation carriers (GBA1-PD) or non-carriers (nonGBA1-PD). Collected data included motor and non-motor parameters. Molecular and clinical differences were compared between GBA1-PD and nonGBA1-PD. Distinctive clinical features were further investigated through multivariate models to test their correlations with biochemical data. RESULTS: The cohort included 611 subjects (225 GBA1-PD, 386 nonGBA1-PD). GBA1-PD presented earlier onset, lower cognitive scores, higher incidence of mood disturbances and more advanced stage. Motor assessment revealed a higher frequency and severity of dyskinesias, independently from disease duration and LEDD. GlcSph levels showed an independent correlation with dyskinesia severity and time at onset in GBA1-PD patients, which was independent of sex, LEDD, UPDRS-III, disease duration and GBA1 mutation class. CONCLUSIONS: This study reveals an association between GlcSph and dyskinesias in GBA1-PD, that should prompt further investigation to assess the GlcSph role as a possible biomarker and target to tackle dyskinesias in GBA1-PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Neurology, Neurophysiology, Neurobiology and Psychiatry, Department of Medicine, University Campus Bio-Medico of Rome, Rome, Italy; Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy. Electronic…
- Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), Palermo, Italy.
- Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
- Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; IRCCS Mondino Foundation, Pavia, Italy.
- Department of Systems Medicine, University of Rome 'Tor Vergata', Rome, Italy; Parkinson's Disease Unit, University Hospital of Rome 'Tor Vergata', Rome, Italy.
- Dino Ferrari Center, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit, Milan, Italy.
Förderung
- Ministero della Salute
Zitieren
APA
Marano, M., Zizzo, C., Cavallieri, F., Avenali, M., Schirinzi, T., Monfrini, E., Spagnolo, F., De Micco, R., Ramat, S., Malaguti, M. C., Reali, F., Cilia, R., Carecchio, M., Pilotto, A., Erro, R., di Vico, I. A., Meloni, M., Di Lazzaro, G., Pietracupa, S., …, & Di Fonzo, A. (2026). Association between plasma glucosylsphingosine levels and dyskinesia burden in GBA1-related Parkinson's disease. Neurobiology of Disease, 219, 107271. https://doi.org/10.1016/j.nbd.2026.107271
Vancouver
Marano M, Zizzo C, Cavallieri F, Avenali M, Schirinzi T, Monfrini E, et al. Association between plasma glucosylsphingosine levels and dyskinesia burden in GBA1-related Parkinson's disease. Neurobiology of Disease. 2026;219:107271. doi:10.1016/j.nbd.2026.107271
BibTeX
@article{Marano2026,
author = {Marano, Massimo and Zizzo, Carmela and Cavallieri, Francesco and Avenali, Micol and Schirinzi, Tommaso and Monfrini, Edoardo and Spagnolo, Francesca and De Micco, Rosa and Ramat, Silvia and Malaguti, Maria Chiara and Reali, Federico and Cilia, Roberto and Carecchio, Miryam and Pilotto, Andrea and Erro, Roberto and di Vico, Ilaria Antonella and Meloni, Mario and Di Lazzaro, Giulia and Pietracupa, Sara and Ledda, Claudia and Mostile, Giovanni and Mascia, Marcello Mario and Fioravanti, Valentina and di Rauso, Giulia and Bovenzi, Roberta and Aloisio, Simone and Liccari, Marco and Bacchin, Ruggero and Colucci, Fabiana and Bonato, Giulia and Lupini, Alessandro and Magliozzi, Alessandro and Sorrentino, Cristiano and Leo, Francesca and Franco, Giulia and Modugno, Nicola and Zibetti, Maurizio and Arabia, Gennarina and Bentivoglio, Anna Rita and Caputo, Elena and Tamma, Filippo and Padovani, Alessandro and Zappia, Mario and Eleopra, Roberto and Tinazzi, Michele and Fabbrini, Giovanni and Tessitore, Alessandro and Di Lazzaro, Vincenzo and Valente, Enza Maria and Duro, Giovanni and Di Fonzo, Alessio},
title = {Association between plasma glucosylsphingosine levels and dyskinesia burden in GBA1-related Parkinson's disease},
journal = {Neurobiology of Disease},
year = {2026},
volume = {219},
pages = {107271},
doi = {10.1016/j.nbd.2026.107271}
}
EUVIMED